Exome Asset Management LLC
Long book
$169.9M
Q1 2026
Positions
45
Top-10 weight
46%
concentration
Last quarter
+19.0%
SPY +14.8%
Turnover
54%
of book per quarter
Strategy in plain words
auto-generated from filingsExome Asset Management LLC is a diversified fundamental manager, specialised in healthcare (95% of the long book), running a $169.9M US long book across 45 positions.
The portfolio is moderately concentrated (top 10 ≈ 46% of the book). Turnover is high — positions rotate quickly, so individual names matter less than the process. Current anchor positions: PRAXIS PRECISION MEDICINES I, COGENT BIOSCIENCES INC, ENLIVEN THERAPEUTICS INC, IONIS PHARMACEUTICALS INC, GUARDANT HEALTH INC.
Over the last 9 quarters its long book ran on average 6.9pp per quarter ahead of the S&P 500, beating the index in 4 of 9 quarters. We rate its filings as signal-bearing: position changes reflect genuine views.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q1 2024
+4.2%
Q2 2024
+3.9%
Q3 2024
-1.3%
Q4 2024
-12.8%
Q1 2025
+9.1%
Q2 2025
+26.9%
Q3 2025
+54.5%
Q4 2025
-0.9%
Q1 2026
+19.0%
Sector allocation
Healthcare 92%
Financials 5%
Other 3%
Long book by quarter
What does Exome Asset own?
Q1 2026 13F| Company | Sector | Shares | Value | % of book | Change |
|---|---|---|---|---|---|
| PRAX PRAXIS PRECISION MEDICINES I | Healthcare | 45.5K | $14.6M | 8.6% | -21.8% |
| COGT COGENT BIOSCIENCES INC | Healthcare | 278.5K | $10.7M | 6.3% | -8.8% |
| ELVN ENLIVEN THERAPEUTICS INC | Healthcare | 220.1K | $8.6M | 5.1% | -1.0% |
| IONS IONIS PHARMACEUTICALS INC | Healthcare | 110.1K | $8.3M | 4.9% | -5.5% |
| GH GUARDANT HEALTH INC | Healthcare | 82.7K | $7.6M | 4.5% | -15.7% |
| CYTK CYTOKINETICS INC | Healthcare | 103.7K | $6.8M | 4.0% | -16.9% |
| LLY ELI LILLY & CO | Healthcare | 7.0K | $6.4M | 3.8% | -10.7% |
| ALMS ALUMIS INC | Healthcare | 279.2K | $6.2M | 3.6% | -4.5% |
| BBIO BRIDGEBIO PHARMA INC | Healthcare | 67.5K | $5.0M | 2.9% | -16.4% |
| VERA VERA THERAPEUTICS INC | Healthcare | 115.0K | $4.6M | 2.7% | -7.6% |
| INSM INSMED INC | Healthcare | 26.7K | $4.4M | 2.6% | New |
| ELV ELEVANCE HEALTH INC | Financials | 14.7K | $4.3M | 2.5% | -14.6% |
| AGIO AGIOS PHARMACEUTICALS INC | Healthcare | 125.1K | $4.2M | 2.5% | -8.7% |
| UTHR UNITED THERAPEUTICS CORP | Healthcare | 7.1K | $4.2M | 2.5% | -8.2% |
| MLTX MOONLAKE IMMUNOTHERAPEUTICS | Healthcare | 215.4K | $4.0M | 2.4% | New |
| NTRA NATERA INC | Healthcare | 18.6K | $3.7M | 2.2% | Held |
| RYTM RHYTHM PHARMACEUTICALS INC | Healthcare | 40.6K | $3.5M | 2.1% | New |
| UNH UNITEDHEALTH GROUP INC | Financials | 12.9K | $3.5M | 2.0% | +120.4% |
| APLSUSD APELLIS PHARMACEUTICALS INC | — | 85.5K | $3.4M | 2.0% | -37.0% |
| VSTM VERASTEM INC | Healthcare | 636.7K | $3.4M | 2.0% | +58.5% |
| TXG 10X GENOMICS INC-CLASS A | Healthcare | 154.2K | $3.3M | 1.9% | -5.8% |
| BSX BOSTON SCIENTIFIC CORP | Healthcare | 48.3K | $3.0M | 1.8% | New |
| ALKS ALKERMES PLC | Healthcare | 84.1K | $3.0M | 1.7% | New |
| GLUE MONTE ROSA THERAPEUTICS INC | Healthcare | 179.5K | $3.0M | 1.7% | New |
| ISRG INTUITIVE SURGICAL INC | Healthcare | 6.4K | $2.9M | 1.7% | Held |
| ARWR ARROWHEAD PHARMACEUTICALS IN | Healthcare | 45.7K | $2.9M | 1.7% | -8.1% |
| CBIO CRESCENT BIOPHARMA INC | Healthcare | 153.2K | $2.8M | 1.7% | New |
| RLAY RELAY THERAPEUTICS INC | Healthcare | 278.3K | $2.8M | 1.6% | New |
| MAZE MAZE THERAPEUTICS INC | Healthcare | 88.5K | $2.6M | 1.6% | New |
| CTMX CYTOMX THERAPEUTICS INC | Healthcare | 521.5K | $2.5M | 1.4% | -30.0% |
| AVTX AVALO THERAPEUTICS INC | Healthcare | 159.3K | $2.4M | 1.4% | New |
| GKOS GLAUKOS CORP | Healthcare | 20.9K | $2.2M | 1.3% | -33.7% |
| CRBP CORBUS PHARMACEUTICALS HOLDI | Healthcare | 234.1K | $2.2M | 1.3% | +67.8% |
| PEN PENUMBRA INC | Healthcare | 6.3K | $2.1M | 1.2% | -30.0% |
| SLNOEUR SOLENO THERAPEUTICS INC | — | 61.7K | $2.1M | 1.2% | New |
| LQDA LIQUIDIA CORP | Healthcare | 45.8K | $1.7M | 1.0% | -49.8% |
| ZBIO ZENAS BIOPHARMA INC | Healthcare | 80.7K | $1.6M | 0.9% | New |
| FDMT 4D MOLECULAR THERAPEUTICS IN | Healthcare | 130.6K | $1.2M | 0.7% | New |
| NXTC NEXTCURE INC | Healthcare | 115.5K | $1.2M | 0.7% | -30.0% |
| PALI PALISADE BIO INC | Healthcare | 600.0K | $1.1M | 0.6% | -20.9% |
| ESTA ESTABLISHMENT LABS HOLDINGS | Healthcare | 13.1K | $744K | 0.4% | Held |
| LPCN LIPOCINE INC | Healthcare | 60.9K | $486K | 0.3% | New |
| ABUS ARBUTUS BIOPHARMA CORP | Healthcare | 75.5K | $340K | 0.2% | Held |
13F filing history
| Period | Form | Filed | Entries | Reported value | Flags | Source |
|---|---|---|---|---|---|---|
| Q1 2026 | 13F-HR | May 15, 2026 | 56 | $193.3M | canonical | SEC ↗ |
| Q4 2025 | 13F-HR | Feb 13, 2026 | 60 | $209.1M | canonical | SEC ↗ |
| Q3 2025 | 13F-HR | Nov 14, 2025 | 68 | $165.1M | canonical | SEC ↗ |
| Q2 2025 | 13F-HR/ARESTATEMENT | Aug 15, 2025 | 63 | $134.5M | canonical | SEC ↗ |
| Q2 2025 | 13F-HR | Aug 14, 2025 | 64 | $134.5M | SEC ↗ | |
| Q1 2025 | 13F-HR/ARESTATEMENT | May 16, 2025 | 59 | $112.5M | canonical | SEC ↗ |
| Q1 2025 | 13F-HR | May 15, 2025 | 59 | $112.5M | SEC ↗ | |
| Q4 2024 | 13F-HR | Feb 14, 2025 | 59 | $133.1M | canonical | SEC ↗ |
| Q3 2024 | 13F-HR/ANEW HOLDINGS | Dec 13, 2024 | 59 | $147.9M | canonical | SEC ↗ |
| Q3 2024 | 13F-HR | Nov 14, 2024 | 56 | $145.6M | canonical | SEC ↗ |
| Q2 2024 | 13F-HR/ARESTATEMENT | Oct 3, 2024 | 52 | $112.3M | canonical | SEC ↗ |
| Q2 2024 | 13F-HR | Aug 14, 2024 | 50 | $114.8M | SEC ↗ | |
| Q1 2024 | 13F-HR | May 15, 2024 | 53 | $116.8M | canonical | SEC ↗ |